Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Memorial Sloan Kettering Cancer Center.
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT01866293
First received: May 28, 2013
Last updated: November 6, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)